RAFAEL HOLDINGS, INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- RAFAEL HOLDINGS, INC. treasury stock, value, acquired, cost method for the quarter ending 2024-07-31 was $0.00.
- RAFAEL HOLDINGS, INC. treasury stock, value, acquired, cost method for the quarter ending 2024-04-30 was $0.00.
- RAFAEL HOLDINGS, INC. treasury stock, value, acquired, cost method for the quarter ending 2024-01-31 was $89.00K.
- RAFAEL HOLDINGS, INC. treasury stock, value, acquired, cost method for the quarter ending 2023-10-31 was $79.00K.
- RAFAEL HOLDINGS, INC. treasury stock, value, acquired, cost method for fiscal 2024 was $168.00K.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2024-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $168.00K 10-K · filed 2025-10-29 |
| 2024-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11 | |
| 2024-01-31 | $89.00K 10-Q · filed 2025-03-14 | |
| 2023-10-31 | $79.00K 10-Q · filed 2024-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |